L-Carnitine is a quaternary ammonium compound biosynthesized from lysine and methionine that plays a critical role in energy metabolism. It acts as an obligate cofactor for the carnitine palmitoyltransferase (CPT) enzyme system, which shuttles long-chain fatty acids across the inner mitochondrial membrane for β-oxidation[1]. This process is essential for ATP production from fat stores, particularly during prolonged exercise or caloric restriction. Clinical and preclinical studies indicate L-Carnitine supplementation can enhance fat oxidation, reduce body weight, and improve exercise performance in certain populations[2][5]. A meta-analysis of 37 randomized controlled trials found approximately 2,000 mg/day oral L-Carnitine yields modest weight-loss effects (~1.2 kg), with diminishing returns above that dose[2]. Why subcutaneous over oral? Oral L-Carnitine has poor bioavailability (5–18% at high doses) due to saturable intestinal absorption[3]. Furthermore, unabsorbed carnitine is metabolized by gut bacteria into trimethylamine (TMA), which is converted to trimethylamine-N-oxide (TMAO) in the liver—a metabolite linked to increased cardiovascular risk[4][9]. Subcutaneous or intravenous administration provides 100% bioavailability and bypasses TMAO production, as demonstrated in animal models where parenteral L-Carnitine did not promote atherosclerosis unlike oral dosing[4]. In hemodialysis patients with carnitine deficiency, intravenous L-Carnitine (10–40 mg/kg after dialysis sessions) significantly increased plasma carnitine levels, reduced fatigue, and preserved exercise capacity over 24 weeks with excellent tolerability[5]. High-dose intravenous protocols (up to 50 mg/kg daily, ~3,500 mg for a 70 kg person) have been used safely in patients with metabolic disorders[8], indicating a wide therapeutic margin.
